Medicine Jazz Pharmaceuticals Completes Biologics License Application for Zanidatamab for HER2-Positive Metastatic Biliary Tract Cancer April 2, 2024 admin Approval would mark first HER2-targeted therapy for biliary tract cancer in the United States. Share Facebook Twitter Pinterest Linkedin